ArticleRheumatology (Oxford, England)2017
Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies.
Article in Rheumatology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association.PloS one · 2018Trial
- Beyond Sequence: Posttranslational Remodeling of Antigens in Autoimmunity.Immunological reviews · 2026Review
- Molecular basis of post-translational neoantigen generation in rheumatoid arthritis: breaking immunological tolerance and implications for targeted therapy.Frontiers in immunology · 2026Review
- Review
- Albumins represent highly cross-reactive animal allergens.Frontiers in immunology · 2023Review
- Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.Frontiers in immunology · 2023Article
- Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis.Diagnostics (Basel, Switzerland) · 2022Article
- Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis.Rheumatology (Oxford, England) · 2022Article
- Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?International journal of molecular sciences · 2022Review
- Phage-Display-Derived Peptide Specific to Carbamylated Protein.ACS omega · 2021Article
- Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset RecognizingFrontiers in immunology · 2021Article
- Carbamylation reduces the capacity of IgG for hexamerization and complement activation.Clinical and experimental immunology · 2020Article
- Review
- Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders.Internal medicine (Tokyo, Japan) · 2019Review
- Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients.PloS one · 2018Article
- Complement in the Initiation and Evolution of Rheumatoid Arthritis.Frontiers in immunology · 2018Review
- Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis.Arthritis research & therapy · 2017Article
- Mechanisms and consequences of carbamoylation.Nature reviews. Nephrology · 2017Review
- Vitamin Status as Predictors in Rheumatoid Arthritis.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Anti-carbamylated protein (anti-CarP) antibodies are detected in RA patients. Fetal calf serum is used as an antigen source in anti-CarP ELISA, and the precise target antigens have not been found. We aimed to identify the target antigens of anti-CarP antibodies. Methods: Western blotting of anti-CarP antibodies was conducted. Anti-carbamylated human albumin (CarALB) antibody was detected by in-house ELISA for 493 RA patients and 144 healthy controls (HCs). An inhibition ELISA of anti-CarP antibodies by CarALB and citrullinated albumin (citALB) was performed using eight RA patients' sera. Serum CarALB was detected by liquid chromatography-tandem mass spectroscopy (LC/MS/MS), and the serum MPO concentration was measured by ELISA. Results: We focused on carbamylated albumin because it corresponded to the size of the thickest band detected by western blotting of anti-CarP antibodies. Anti-CarALB antibody was detected in 31.4% of RA patients, and the correlation of the titres between anti-CarALB and anti-CarP was much closer than that between anti-citALB and anti-CCP antibodies (ρ = 0.59 and ρ = 0.16, respectively). The inhibition ELISA showed that anti-CarP antibodies were inhibited by CarALB, but not by citALB. CarALB was detected in sera from RA patients by LC/MS/MS. The serum MPO concentration was correlated with disease activity and was higher in RA patients with anti-CarALB antibody than in those without. Conclusion: We found that carbamylated albumin is a novel target antigen of anti-CarP antibodies, and it is the first reported target antigen that has not been reported as the target of ACPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.